ZA200401360B - Hdl for the treatment of stroke and other ischemic conditions - Google Patents
Hdl for the treatment of stroke and other ischemic conditions Download PDFInfo
- Publication number
- ZA200401360B ZA200401360B ZA2004/01360A ZA200401360A ZA200401360B ZA 200401360 B ZA200401360 B ZA 200401360B ZA 2004/01360 A ZA2004/01360 A ZA 2004/01360A ZA 200401360 A ZA200401360 A ZA 200401360A ZA 200401360 B ZA200401360 B ZA 200401360B
- Authority
- ZA
- South Africa
- Prior art keywords
- hdl
- treatment
- administered
- ischemia
- rhdl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 230000000302 ischemic effect Effects 0.000 title claims description 11
- 208000006011 Stroke Diseases 0.000 title abstract description 20
- 238000001802 infusion Methods 0.000 claims abstract description 17
- 238000011321 prophylaxis Methods 0.000 claims abstract description 13
- 238000001990 intravenous administration Methods 0.000 claims abstract description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 68
- 208000028867 ischemia Diseases 0.000 claims description 15
- 230000010410 reperfusion Effects 0.000 claims description 10
- 102000007592 Apolipoproteins Human genes 0.000 claims description 9
- 108010071619 Apolipoproteins Proteins 0.000 claims description 9
- 206010063837 Reperfusion injury Diseases 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 150000001840 cholesterol esters Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 208000037906 ischaemic injury Diseases 0.000 abstract description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 44
- 241000700159 Rattus Species 0.000 description 30
- 210000004556 brain Anatomy 0.000 description 14
- 210000003657 middle cerebral artery Anatomy 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000001052 transient effect Effects 0.000 description 7
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 6
- 206010049771 Shock haemorrhagic Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000001338 necrotic effect Effects 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 231100000318 excitotoxic Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 244000202285 Acrocomia mexicana Species 0.000 description 1
- 235000003625 Acrocomia mexicana Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101100382264 Mus musculus Ca14 gene Proteins 0.000 description 1
- 101100112373 Mus musculus Ctsm gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100094962 Salmo salar salarin gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- -1 hydroxyl anions Chemical class 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31360501P | 2001-08-20 | 2001-08-20 | |
| EP01120026A EP1285662A1 (en) | 2001-08-20 | 2001-08-20 | Reconstituted HDL for the treatment of stroke and ischemic conditions |
| PCT/EP2002/009294 WO2003018047A2 (en) | 2001-08-20 | 2002-08-20 | Hdl for the treatment of stroke and other ischemic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401360B true ZA200401360B (en) | 2005-08-31 |
Family
ID=26076691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2004/01360A ZA200401360B (en) | 2001-08-20 | 2004-02-19 | Hdl for the treatment of stroke and other ischemic conditions |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040266660A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1425031B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4284177B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE396736T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002340825B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2457840C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60226881D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2304452T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003018047A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200401360B (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1668645A (zh) * | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2007000924A1 (ja) * | 2005-06-28 | 2007-01-04 | Osaka University | プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法 |
| US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
| AU2007200908B2 (en) * | 2007-03-01 | 2012-08-16 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| JP5601750B2 (ja) * | 2007-03-01 | 2014-10-08 | シーエスエル、リミテッド | 糖尿病患者の内皮機能異常の治療 |
| WO2010151096A1 (en) | 2009-06-25 | 2010-12-29 | Tetra, Sia | Therapeutic combinations of nicotinic acid and meldonium |
| WO2011006994A1 (en) | 2009-07-16 | 2011-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hdl comprising a therapeutic agent and use in therapy |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
| US12419839B2 (en) | 2009-10-09 | 2025-09-23 | Signablok, Inc. | Methods and compositions for targeted delivery of protein fragments |
| US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
| CN105288589A (zh) | 2011-02-07 | 2016-02-03 | 塞勒尼斯医疗控股公司 | 脂蛋白复合物及其制备和用途 |
| EP2688584A4 (en) * | 2011-03-25 | 2015-05-20 | Univ Columbia | PEGYLATED HUMAN HDL PARTICLES AND METHOD OF PREPARING THEM |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| ES2984285T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Cargómeros |
| ES2984286T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| WO2021191266A1 (en) | 2020-03-25 | 2021-09-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hdl for the treatment of lung infections |
| WO2021209823A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein- based complexes |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| US20230372532A1 (en) * | 2020-10-05 | 2023-11-23 | Northwestern University | Targeted ph sensitive liposomes |
| US20240215570A1 (en) | 2021-04-15 | 2024-07-04 | Abionyx Pharma Sa | Use of lipid binding protein-based complexes in organ preservation solutions |
| WO2023194797A1 (en) | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| WO2023237927A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| AU2023284357A1 (en) | 2022-06-10 | 2025-01-23 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
| IL322074A (en) | 2023-01-13 | 2025-09-01 | Abionyx Pharma Sa | Treatment using a lipid-binding protein molecule |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| GB9919713D0 (en) * | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AUPQ429399A0 (en) | 1999-11-26 | 1999-12-23 | Heart Research Institute, The | Oxidized apolipoproteins and methods of use |
-
2002
- 2002-08-20 EP EP02774525A patent/EP1425031B8/en not_active Expired - Lifetime
- 2002-08-20 US US10/487,224 patent/US20040266660A1/en not_active Abandoned
- 2002-08-20 JP JP2003522564A patent/JP4284177B2/ja not_active Expired - Fee Related
- 2002-08-20 ES ES02774525T patent/ES2304452T3/es not_active Expired - Lifetime
- 2002-08-20 AU AU2002340825A patent/AU2002340825B2/en not_active Ceased
- 2002-08-20 WO PCT/EP2002/009294 patent/WO2003018047A2/en not_active Ceased
- 2002-08-20 AT AT02774525T patent/ATE396736T1/de active
- 2002-08-20 DE DE60226881T patent/DE60226881D1/de not_active Expired - Lifetime
- 2002-08-20 CA CA2457840A patent/CA2457840C/en not_active Expired - Fee Related
-
2004
- 2004-02-19 ZA ZA2004/01360A patent/ZA200401360B/en unknown
-
2007
- 2007-05-04 US US11/744,780 patent/US7491693B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7491693B2 (en) | 2009-02-17 |
| CA2457840C (en) | 2011-10-11 |
| EP1425031A2 (en) | 2004-06-09 |
| ES2304452T3 (es) | 2008-10-16 |
| HK1064304A1 (en) | 2005-01-28 |
| WO2003018047A2 (en) | 2003-03-06 |
| US20080108550A1 (en) | 2008-05-08 |
| JP4284177B2 (ja) | 2009-06-24 |
| AU2002340825B2 (en) | 2007-07-05 |
| DE60226881D1 (de) | 2008-07-10 |
| ATE396736T1 (de) | 2008-06-15 |
| US20040266660A1 (en) | 2004-12-30 |
| CA2457840A1 (en) | 2003-03-06 |
| EP1425031B1 (en) | 2008-05-28 |
| JP2005501110A (ja) | 2005-01-13 |
| WO2003018047A3 (en) | 2004-01-29 |
| EP1425031B8 (en) | 2008-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7491693B2 (en) | HDL for the treatment of stroke and other ischemic conditions | |
| AU2002340825A1 (en) | HDL for the treatment of stroke and other ischemic conditions | |
| KR101668137B1 (ko) | 계면 활성 단백질 ｂ (ｓｐ－ｂ) 및 계면 활성 단백질 ｃ (ｓｐ－ｃ)의 유사체를 함유하는 개량된 재구성 계면 활성제 조성물 | |
| JPH05506034A (ja) | アクチン結合性化合物の療法的使用 | |
| CN1248169A (zh) | 含有3－环丙基甲氧基－n－(3,5－二氯－4－吡啶基)－4－(二氟甲氧基)苯甲酰胺和肺表面活性剂的治疗ards或irds的组合物 | |
| KR20230051721A (ko) | 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합 | |
| WO2022009081A1 (en) | Drug for use against the novel coronavirus disease, covid-19 | |
| JP2024166198A (ja) | 可溶性細胞外マトリックス組成物および血管内送達のための方法 | |
| CN1203861C (zh) | 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂 | |
| JPH02264730A (ja) | Ａｔｌｌ治療用吸入剤 | |
| US20170209498A1 (en) | Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerve | |
| EP0588477A2 (en) | Medicinal composition comprising TCF-II | |
| EP1057489B1 (en) | Use of midkine family proteins in the treatment of ischemic diseases | |
| HK1064304B (en) | Hdl for the treatment of stroke and other ischemic conditions | |
| NO321126B1 (no) | Salt av et BPC (Body protection compound) "kroppsbeskyttelsesforbindelse"-peptid, omfattende 8 aminosyrerester, kompatibelt, lagringsstabilt, farmasoytisk preparat, diagnostisk lagringsstabilt preparat, anvendelser og fremgangsmater derav. | |
| EP1285662A1 (en) | Reconstituted HDL for the treatment of stroke and ischemic conditions | |
| WO2003061680A3 (en) | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease | |
| TWI311485B (en) | Reconstituted hdl for the treatment of stroke and ischemic conditions | |
| US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| CN109568263B (zh) | 一种治疗脑梗死的穴位注射剂及其用途 | |
| RU2290194C1 (ru) | Антитромботическое, антикоагулянтное, фибриндеполимеризационное, фибринолитическое средство | |
| KR101768809B1 (ko) | 덱사메타손 및 글리벤클라마이드를 포함하는 뇌졸중의 예방 또는 치료용 약학적 조성물 | |
| HK1026145B (en) | A composition for the treatment of irds and ards | |
| CN1695735A (zh) | 人尿激肽原酶在制备脓毒症药物中的应用 | |
| HK1125048A1 (en) | Method for treating or preventing ischemia reperfusion injury or multi-organ failure |